Asthma is not classified as an autoimmune disease. It is a chronic inflammatory condition of the airways, driven primarily by an overreaction to external triggers like allergens, pollution, or infections rather than by the immune system attacking the body’s own tissues. That said, the line is blurrier than most people realize, especially in severe asthma, where researchers have found signs of autoimmune activity that challenge the clean separation between these two categories.
What Makes a Disease Autoimmune
For a disease to qualify as autoimmune, the tissue damage must be caused by an adaptive immune response directed at the body’s own proteins or cells. Rheumatoid arthritis, type 1 diabetes, and lupus all meet this standard: the immune system identifies something in the body as foreign and mounts a sustained attack against it. The damage comes from within, not from an outside invader.
Asthma doesn’t fit this pattern in most cases. The hallmark immune response in asthma is directed outward, at things like pollen, dust mites, mold, or pet dander. Your immune system overreacts to these harmless substances as though they were dangerous, producing inflammation that narrows the airways and makes breathing difficult. The target is external, not internal, which is the key distinction.
How Typical Asthma Works
In allergic asthma, the most common form, the immune system produces large amounts of an antibody called IgE in response to an allergen. IgE latches onto mast cells in the airways. The next time you encounter that allergen, the IgE-coated mast cells release a flood of inflammatory chemicals that cause airway swelling, mucus production, and muscle tightening around the bronchial tubes. This cascade is orchestrated by a branch of immune cells called Th2 cells, which also recruit eosinophils, a type of white blood cell closely linked to allergic inflammation.
Non-allergic asthma follows a different path but still isn’t autoimmune. Triggers like cigarette smoke, air pollution, diesel particles, and viral infections can provoke airway inflammation without any allergen involvement. Pollution-driven asthma, for example, relies on a different immune signaling molecule (IL-17) and tends to involve neutrophils rather than eosinophils. Viral infections can trigger asthma through interactions between specialized lung immune cells and natural killer T cells. In all of these cases, the immune system is reacting to something from outside the body.
The Autoimmune Signal in Severe Asthma
Here’s where it gets more complicated. A growing body of evidence shows that some people with severe asthma do produce autoantibodies, immune proteins that target the body’s own tissues. This is one of the defining features of autoimmune disease, and it appears at rates far higher than you’d expect from chance alone.
In one observational study of 95 asthma patients, 22% tested positive for antinuclear antibodies (ANAs), a common marker of autoimmune activity. Among healthy people, only 3.3% were positive. Those asthma patients with ANAs had worse outcomes across the board: higher mortality risk, more hospitalizations for severe flare-ups, and faster decline in lung function (losing more than 100 mL of lung capacity per year).
Researchers have also found autoantibodies targeting collagen V, a structural protein in the lungs, at significantly higher levels in asthma patients compared to healthy controls. The antibody levels were highest in people with the most severe disease. Separately, about 37% of eosinophilic asthmatics in another study had autoantibodies in their airway mucus that targeted eosinophil peroxidase, a protein released by their own eosinophils. Lung biopsies from severe asthmatics have even revealed granulomas, clusters of immune cells that form around perceived threats and are a hallmark of several autoimmune and inflammatory conditions.
Perhaps most telling, some patients with these airway autoantibodies respond poorly to targeted biologic therapies designed to reduce eosinophil counts. The treatment removes the eosinophils, but the autoimmune component of the inflammation persists.
Allergic vs. Non-Allergic vs. Autoimmune
It helps to think of asthma not as a single disease but as a family of conditions that all produce similar symptoms (wheezing, breathlessness, chest tightness) through different immune pathways. Allergic asthma is the most common subtype and is clearly not autoimmune. Non-allergic asthma triggered by pollution or infections also falls outside the autoimmune definition. But severe eosinophilic asthma, particularly cases that resist standard treatment, may involve a genuine autoimmune component where the immune system begins targeting the body’s own airway proteins.
The autoantibody evidence scales with severity. In one study examining immune responses to a bronchodilator drug, the presence of interfering antibodies was found in 83% of severe asthmatics, 58% of moderate cases, and just 23% of mild cases. This gradient suggests that autoimmune mechanisms may develop as chronic inflammation progresses, rather than being present from the start.
Why the Distinction Matters for Treatment
The practical reason this question matters is treatment. Standard asthma therapies, including inhaled corticosteroids and allergen avoidance, work well for most people because they target the allergic inflammatory pathway. Newer biologic treatments go a step further by blocking specific immune signals like IgE or the cytokines that recruit eosinophils.
But if a subset of severe asthma involves autoimmune mechanisms, those patients may need different approaches. Some drugs originally developed for autoimmune conditions have shown early promise in asthma. Tocilizumab, which blocks an inflammatory signal called IL-6 and is used for rheumatoid arthritis, improved lung function and reduced steroid dependence in two reported pediatric cases of severe non-allergic asthma. Daclizumab, which inhibits immune cell activation and is used in multiple sclerosis, reduced daytime asthma symptoms and prolonged the time between flare-ups in an 88-patient trial. These crossover results hint that the immune machinery driving some severe asthma cases overlaps meaningfully with what drives recognized autoimmune diseases.
Not every autoimmune drug works for asthma, though. Secukinumab, used for psoriasis and psoriatic arthritis, showed no benefit in uncontrolled asthma and was abandoned during trials. The overlap between asthma and autoimmunity is real but selective, affecting specific pathways rather than the entire immune landscape.
The Bottom Line on Classification
Asthma as a whole is not an autoimmune disease. The vast majority of cases are driven by allergic or environmental triggers, with the immune system reacting to external substances rather than attacking the body. But the picture is more nuanced than a simple “no.” In severe asthma, autoantibodies are present at rates far exceeding those in healthy people, and they correlate with worse lung function, more hospitalizations, and higher mortality. Whether this means severe asthma should eventually be reclassified, or whether it represents a secondary autoimmune process layered on top of chronic inflammation, remains an open question. For now, asthma sits in its own category: a chronic inflammatory airway disease with autoimmune features at its most severe end.